INCYTE CORPORATION Increase (Decrease) in Deferred Income Taxes
INCYTE CORPORATION (INCY) reported Increase (Decrease) in Deferred Income Taxes of -$247.69 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-10.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInDeferredIncomeTaxes · last filed 2026-02-10
- INCYTE CORPORATION increase (decrease) in deferred income taxes for the quarter ending 2025-12-31 was -$13.50M.
- INCYTE CORPORATION increase (decrease) in deferred income taxes for the quarter ending 2025-09-30 was -$124.12M, a 466.39% decline year-over-year.
- INCYTE CORPORATION increase (decrease) in deferred income taxes for the quarter ending 2025-06-30 was -$116.78M, a 767.98% decline year-over-year.
- INCYTE CORPORATION increase (decrease) in deferred income taxes for the quarter ending 2025-03-31 was $6.71M, a 80.42% decline year-over-year.
- INCYTE CORPORATION increase (decrease) in deferred income taxes for fiscal 2025 was -$247.69M, a 389.51% decline from fiscal 2024.
- INCYTE CORPORATION increase (decrease) in deferred income taxes for fiscal 2024 was $85.55M, a 46.16% decline from fiscal 2023.
- INCYTE CORPORATION increase (decrease) in deferred income taxes for fiscal 2023 was $158.90M.
- INCYTE CORPORATION increase (decrease) in deferred income taxes for fiscal 2022 was -$57.09M, a 112.26% decline from fiscal 2021.
| Period end | Increase (Decrease) in Deferred Income Taxes 3 month | Increase (Decrease) in Deferred Income Taxes 6 month | Increase (Decrease) in Deferred Income Taxes 9 month | Increase (Decrease) in Deferred Income Taxes 12 month |
|---|---|---|---|---|
| 2025-12-31 | -$13.50M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-10 | -$137.61M derived: sum of 2 quarters · filed 2026-02-10 | -$254.39M derived: sum of 3 quarters · filed 2026-02-10 | -$247.69M 10-K · filed 2026-02-10 |
| 2025-09-30 | -$124.12M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-28 | -$240.89M derived: sum of 2 quarters · filed 2025-10-28 | -$234.19M 10-Q · filed 2025-10-28 | -$234.24M derived: sum of 4 quarters · filed 2026-02-10 |
| 2025-06-30 | -$116.78M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-29 | -$110.07M 10-Q · filed 2025-07-29 | -$110.13M derived: sum of 3 quarters · filed 2026-02-10 | -$76.25M derived: sum of 4 quarters · filed 2026-02-10 |
| 2025-03-31 | $6.71M 10-Q · filed 2025-04-29 | $6.65M derived: sum of 2 quarters · filed 2026-02-10 | $40.53M derived: sum of 3 quarters · filed 2026-02-10 | $58.01M derived: sum of 4 quarters · filed 2026-02-10 |
| 2024-12-31 | -$56.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-10 | $33.82M derived: sum of 2 quarters · filed 2026-02-10 | $51.30M derived: sum of 3 quarters · filed 2026-02-10 | $85.55M 10-K · filed 2026-02-10 |
| 2024-09-30 | $33.88M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-28 | $51.36M derived: sum of 2 quarters · filed 2025-10-28 | $85.61M 10-Q · filed 2025-10-28 | $151.59M derived: sum of 4 quarters · filed 2026-02-10 |
| 2024-06-30 | $17.48M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-29 | $51.73M 10-Q · filed 2025-07-29 | $117.71M derived: sum of 3 quarters · filed 2026-02-10 | $148.77M derived: sum of 4 quarters · filed 2026-02-10 |
| 2024-03-31 | $34.25M 10-Q · filed 2025-04-29 | $100.23M derived: sum of 2 quarters · filed 2026-02-10 | $131.28M derived: sum of 3 quarters · filed 2026-02-10 | $170.99M derived: sum of 4 quarters · filed 2026-02-10 |
| 2023-12-31 | $65.98M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-10 | $97.03M derived: sum of 2 quarters · filed 2026-02-10 | $136.74M derived: sum of 3 quarters · filed 2026-02-10 | $158.90M 10-K · filed 2026-02-10 |
| 2023-09-30 | $31.05M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-29 | $70.76M derived: sum of 2 quarters · filed 2024-10-29 | $92.92M 10-Q · filed 2024-10-29 | $76.26M derived: sum of 4 quarters · filed 2025-02-10 |
| 2023-06-30 | $39.70M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-07-30 | $61.86M 10-Q · filed 2024-07-30 | $45.20M derived: sum of 3 quarters · filed 2025-02-10 | $37.25M derived: sum of 4 quarters · filed 2025-02-10 |
| 2023-03-31 | $22.16M 10-Q · filed 2024-04-30 | $5.50M derived: sum of 2 quarters · filed 2025-02-10 | -$2.45M derived: sum of 3 quarters · filed 2025-02-10 | -$32.82M derived: sum of 4 quarters · filed 2025-02-10 |
| 2022-12-31 | -$16.66M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-10 | -$24.62M derived: sum of 2 quarters · filed 2025-02-10 | -$54.98M derived: sum of 3 quarters · filed 2025-02-10 | -$57.09M 10-K · filed 2025-02-10 |
| 2022-09-30 | -$7.96M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-10-31 | -$38.33M derived: sum of 2 quarters · filed 2023-10-31 | -$40.43M 10-Q · filed 2023-10-31 | $424.99M derived: sum of 4 quarters · filed 2024-02-13 |
| 2022-06-30 | -$30.37M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-01 | -$32.48M 10-Q · filed 2023-08-01 | $432.95M derived: sum of 3 quarters · filed 2024-02-13 | $432.97M derived: sum of 4 quarters · filed 2024-02-13 |
| 2022-03-31 | -$2.11M 10-Q · filed 2023-05-02 | $463.32M derived: sum of 2 quarters · filed 2024-02-13 | $463.34M derived: sum of 3 quarters · filed 2024-02-13 | $463.57M derived: sum of 4 quarters · filed 2024-02-13 |
| 2021-12-31 | $465.43M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-13 | $465.44M derived: sum of 2 quarters · filed 2024-02-13 | $465.67M derived: sum of 3 quarters · filed 2024-02-13 | $465.60M 10-K · filed 2024-02-13 |
| 2021-09-30 | $18.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-01 | $248.00K derived: sum of 2 quarters · filed 2022-11-01 | $178.00K 10-Q · filed 2022-11-01 | |
| 2021-06-30 | $230.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-02 | $160.00K 10-Q · filed 2022-08-02 | ||
| 2021-03-31 | -$70.00K 10-Q · filed 2022-05-03 | |||
| 2020-12-31 | $350.00K 10-K · filed 2023-02-07 | |||
| 2019-12-31 | $377.00K 10-K · filed 2022-02-08 | |||
| 2018-12-31 | $459.00K 10-K · filed 2021-02-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| IQVIA HOLDINGS INC. (IQV) | United States | $45.926B | 20.54 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B |